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Abstract
Background: Early 2020, a COVID-19 epidemic became a public health emergency of international concern. To
address this pandemic broad testing with an easy, comfortable and reliable testing method is of utmost concern.
Nasopharyngeal (NP) swab sampling is the reference method though hampered by international supply shortages.
A new oropharyngeal/nasal (OP/N) sampling method was investigated using the more readily available throat
swab.
Results: 35 patients were diagnosed with SARS-CoV-2 by means of either NP or OP/N sampling. The paired swabs
were both positive in 31 patients. The one patient who tested negative on both NP and OP/N swab on admission,
was ultimately diagnosed on bronchoalveolar lavage fluid. A strong correlation was found between the viral RNA
loads of the paired swabs (r = 0.76; P < 0.05). The sensitivity of NP and OP/N analysis in hospitalized patients (n = 28)
was 89.3% and 92.7% respectively.
Conclusions: This study demonstrates equivalence of NP and OP/N sampling for detection of SARS-CoV-2 by
means of rRT-PCR. Sensitivity of both NP and OP/N sampling is very high in hospitalized patients.
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Background
A pandemic of respiratory disease caused by SARS-CoV-
2 began in Wuhan, China in December 2019 and quickly
spread to every continent. On February 1st, 2020, the
disease was declared a Public Health Emergency of
International Concern (PHEIC) by the World Health
Organization (WHO). [1] By end 2020, over 80 million
people were infected and almost 1,800,000 died.
Real-time reverse transcriptase-polymerase chain reac-
tion (rRT-PCR) on nasopharyngeal swab material is
typically used to confirm the clinical diagnosis. [1, 2]
Nasopharyngeal (NP) swab remains the reference sam-
pling method, while recent studies suggest that nasal
swab and saliva sampling may be nearly equivalent. [3–
6] The detection of SARS-CoV-2 in oropharyngeal
swabs seems less sensitive. [7–12]
In order to address a pandemic, extensive mapping
and therefore broad testing with an easy and comfort-
able sampling method is of utmost importance. In the
context of an international shortage in nasopharyngeal
swabs, the search for a suitable alternative is a global
health priority. This study evaluates a new combined
oropharyngeal/nasal (OP/N) sampling method using the
more readily available throat swab.
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Results
During the study period, 41 SARS-CoV-2 PCR-confirmed
patients were diagnosed at Ghent University Hospital. Five
patients were excluded because no OP/N swab was sam-
pled upon admission. Seventy-five samples from the 36
remaining patients were analysed. All patients except two
had 2 samples (1 NP and 1 OP/N), one patient had 3 sam-
ples (2 NP, 1 OP/N), one patient had 4 samples (2 NP, 1
OP/N, 1 BAL). The median age was 61 years (range, 22–
90), 21 out of 36 patients (58%) were male and 28 (78%) pa-
tients were hospitalized. Patients were grouped for severity
of illness according to the NIH guidelines: 7/36 showed
mild illness (19%), 10/36 showed moderate illness (28%),
13/36 showed severe illness (36%) and 5/36 were critical ill
(14%). One patient was presymptomatic (3%). Overall, 35/
36 patients were diagnosed with SARS-CoV-2 by means of
either NP or OP/N sampling on admission. The paired
swabs were both positive in 31 patients. In two patients, NP
swabs were positive (Ct 36.47 and 38.38) with negative OP/
N swabs. In two other patients, OP/N swabs were positive
(Ct 34.14 and 41.39) with negative NP swabs. The one pa-
tient who tested negative on both NP and OP/N swab at
admission, was ultimately diagnosed on BAL fluid (Ct
35.80). There was no difference in Ct value, both for OP/N
and NP sampling, among the groups with different severity
of illness (P = 0.459 and P = 0.231, respectively). The 5 pa-
tients (5/36), in whom the paired swabs were not both posi-
tive, belonged to different groups of disease severity (1
mild, 1 moderate, 2 severe, 1 critical ill).
When the paired OP/N and NP samples were compared
in the 31 patients who tested positive in both, the median
Ct for SARS-CoV-2 PCR was not significantly different:
27.5 cycles (range, 15.7–40.4) in NP samples vs. 27.2 cy-
cles (range, 14.1–40.2) (P = 0.576) in OP/N samples.
Besides, a strong correlation was found between the Ct
values of the paired swabs (r = 0.76; P < 0.05) (Fig. 1). In
accordance, quantification of human DNA by real-time
PCR did not show a significant difference in yield be-
tween both methods (data not shown). Of the 28 hospi-
talized patients, 27 were diagnosed by means of either
NP (25) or OP/N (26) sampling. Thus, when considering
a PCR positive result on BAL fluid as the ultimate con-
firmation of COVID-19 diagnosis, sensitivity of NP and
OP/N analysis were 89.3% and 92.7% respectively in hos-
pitalized patients (n = 28).
Discussion
Nasopharyngeal swab is considered to be the reference
sampling method in suspected COVID-19 patients. [3,
Fig. 1 Correlation of viral RNA load (log2 transformed as threshold cycles) in nasopharyngeal sampling and oropharyngeal/nasal sampling. R = 0.76
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4] In the context of an international shortage in naso-
pharyngeal swabs, the search for a suitable alternative is
a burning issue. Moreover, given the need of extensive
population testing, an easy and patient-friendly sampling
method is preferred. Salivary sampling has been reported
as a reliable tool to detect SARS-CoV-2 in COVID-19
patients. This study, however, did only include patients
with severe to very severe disease and did not provide
information on mildly or moderately ill patients. [6]
Nasal sampling was proposed as an alternative to naso-
pharyngeal sampling, though appears to be inferior to
nasopharyngeal sampling (9.1% false negatives). [5] Oro-
pharyngeal (OP) sampling is less sensitive (compared
both to nasopharyngeal and nasal sampling) according
to several studies. Wang X. et al. (2020) and Wang W.
et al. (2020) reported a positivity rate of OP sampling of
27% and 32% respectively in COVID-19 patients. Sensi-
tivity results were not reported. [8, 11]
To our knowledge, our study is the first to show that
the molecular detection of SARS-CoV-2 on combined
OP/N swabs was non-inferior to nasopharyngeal sam-
pling. [3, 4] We found a high correlation between the
viral RNA loads of the paired OP/N and NP samples.
Besides, the sensitivities of both NP and OP/N sampling
in hospitalized patients were 89.3% and 92.7% respect-
ively. Large differences in sensitivity of NP sampling
were published ranging from 63–73.3%. [10, 11, 13] It
should be mentioned however that, to our knowledge,
no peer-reviewed studies or large trials regarding this
subject are available. The gold standard to which tests
under investigation are to be compared, is not clear and
differs among various publications, although consensus
seems to exist about the positioning of BAL fluid as the
most reliable testing method. [10]
Conclusion
This study, performed in symptomatic patients with a
broad age range and various degrees of disease severity,
demonstrates equivalence of NP and OP/N sampling for
detection of SARS-CoV-2 by means of rRT-PCR. Sensi-
tivity of both NP and OP/N sampling is very high in
hospitalized patients. These results warrant further
evaluation of the combined oropharyngeal/nasal testing
strategy in pauci- or asymptomatic individuals in order
to tackle the global shortage in NP swabs. In this con-
text, the new sampling strategy described here was used
by the Belgian Government to guide a national screening
campaign in residential care centres.
Methods
This prospective observational study was conducted at
Ghent University Hospital, Belgium from April 7th to
May 1st, 2020. Upon presentation at the emergency de-
partment, all patients with suspected COVID-19 (based
on respiratory and inflammatory symptoms) in whom a
NP test was indicated for diagnosis, were candidates for
a combined OP/N swab, sampled according to a specific
protocol, developed in Ghent University Hospital. At in-
clusion, no distinction was made based upon disease se-
verity or the need for hospitalization. Hospitalised
patients with highly suspect clinical and radiological fea-
tures of COVID-19 and negative PCR-sample on admis-
sion were retested with an additional NP and/or anal
swab and finally, if still tested negative, on bronchoalve-
olar lavage (BAL) fluid for definite PCR-diagnosis. In
ambulatory patients no retesting was performed. Patients
were grouped for severity of illness according to the
NIH guidelines. [14]
Specimens from OP/N were obtained by rubbing the
oropharyngeal space twice at both sides of the uvula and
placing the same swab into both nasal cavities until a
slight resistance was felt (supposed midturbinate). NP
sampling was performed after OP/N sampling in order
not to ‘contaminate’ the midturbinate part of the nose
by viral material from the nasopharynx as may be ex-
pected when performed in reversed order. Each swab
was rotated three complete turns for optimal mucosal
contact. For NP sampling a flexible mini tip flocked
swab (in Amies transport medium or in universal trans-
port medium (UTM)) was used (Cat. numbers 481CE
and 305C respectively, Copan®, Italy). OP/N sampling
was performed using a non-flexible flocked swab with
normal tip (in Amies transport medium, Cat. number
480CE, Copan®). rRTPCR for SARS-CoV-2 RNA was
performed on both the NP swab and the OP/N swab ac-
cording to Corman et al. [15] using NucliSens easyMag™
RNA extraction (bioMérieux, Marcy-l'Étoile, France) and
one-step rRT-PCR (Qiagen One Step RT-PCR Kit, Cat.
number 210212, Qiagen, Hilden, Germany) on CFX96
cyclers (Bio-Rad, Hercules, USA). All tests were per-
formed in-hospital on a daily basis. A cycle threshold
(Ct) value below 50 for E-gene was interpreted as posi-
tive for SARS-CoV-2 RNA.
All clinical samples were tested for inhibition by add-
ing 7.5 µl of Diagenode RNA extraction and inhibition
Real-Time PCR control (Cat. Number DECR-CY-L100,
Diagenode SA®, Belgium).
Since retesting was not performed in the ambulant pa-
tient group, sensitivity of OP/N and NP sampling was
considered in hospitalized patients only.
Descriptive and relative frequencies were used to de-
scribe the distribution of cases. Since the data were
paired, the Wilcoxon signed-rank test was used to assess
differences between cycle threshold (Ct, considered as
log2 transformed data of quantity viral RNA load) in NP
and OP/N specimens. The Kruskal Wallis test was used
to assess the differences between cycle threshold among
different groups of disease severity. The correlation
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between NP PCR Ct and OP/N PCR Ct was assessed
using Spearman’s rank correlation. Sensitivity was cal-
culated by means of cross tabs. Specificity was found
not to be relevant since not one false positive SARS-
CoV-2 PCR-result was found in this trial period (over
hundred samples), in line with literature. [5] Due to
the nature of this trial, assessing sensitivity without a
negative control group, a calculation of the weighted
kappa coefficient was not relevant. All analyses were
performed using IMB® SPSS® Statistics version 26.
The study was approved by the ethical review board
Ghent University Hospital (BC-07662). The need for
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